NCT04873492
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Recruiting · Not Applicable · Nantes University Hospital · registry updated 2026-03-19
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Inclusion
- Inclusion Criteria :
- Common criteria for retrospective MS patients:
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
- Criteria for Aggressive MS group
Exclusion
- Exclusion Criteria :
- Ongoing participation to a another study
- Refusal to genetic analyses
- Immunosuppressive drug at the time of blood collection
- Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample
- Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)